Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

2d ago, source:

The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who ...

Compass Therapeutics begins patient dosing in phase 1 study of CTX-8371 in patients with solid tumours

1d ago, source: Pharmabiz

Compass Therapeutics begins patient dosing in phase 1 study of CTX-8371 in patients with solid tumours: Boston Wednesday, April 17, 2024, 15:00 Hrs [IST] Compass Therapeutics, Inc ...

CMPX Compass Therapeutics, Inc.

6d ago, source: Seeking Alpha

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.

Compass Therapeutics Stock (NASDAQ:CMPX), Analyst Ratings, Price Targets, Predictions

2d ago, source: Benzinga.com

$1.57 600.64% HC Wainwright & Co.

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

28d ago, source: Yahoo Finance

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based ...

Analysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Compass Therapeutics (CMPX)

2d ago, source:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAB Biotherapeutics (SABS – Research ...

Compass Therapeutics Stock (NASDAQ:CMPX), Quotes and News Summary

1mon ago, source: Benzinga.com

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) rose 65.3% to $12.20 in pre-market trading after gaining around 9% on Friday. Lisa Levin Why Baudax Bio Shares Are Trading Higher By 60%?

Compass Therapeutics Inc Ordinary Shares CMPX

8d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Compass Therapeutics Inc Ordinary Shares

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Compass Therapeutics, Inc. (CMPX)

2d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Compass Therapeutics Inc.

21d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...